Following the authorization of Sputnik V vaccine, the first registered vaccine in Russia, another innovation has been announced. It was revealed that the first dose of Sputnik V, rAd26, which was developed at the Gamaleya Research Institute, demonstrated 79.4% efficacy. This new product, developed under the name of "Sputnik Light", is the first component of Sputnik V, it is a single dose and was licensed in Russia last Friday.

Single dose vaccine, Sputnik Light, authorized for use in Russia Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The Gamaleya Center’s recent preliminary laboratory study shows that Sputnik V demonstrates high virus neutralizing activity (VNA) against the Omicron (B.1.1.529) variant and is expected to provide strong defense against severe disease and hospitalization.